Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis

Curr Osteoporos Rep. 2016 Dec;14(6):249-259. doi: 10.1007/s11914-016-0325-0.

Abstract

It remains unclear if differences in bone mineral density (BMD) exist at different skeletal sites between people with schizophrenia and age- and sex-matched healthy controls (HCs). Major databases were searched from inception until February 2016 for studies measuring BMD using dual-energy X-ray absorptiometry (DXA) at any skeletal site in individuals with schizophrenia. Ten studies investigating 827 people with schizophrenia (55.4 % female, 33.8 ± 9.7 years) and 1379 HCs (58.7 % female, 34.7 ± 9.1 years) were included. People with schizophrenia had significantly reduced BMD at the lumbar spine (standardised mean difference adjusted for publication bias (SMD) = -0.950 (95 % CI = -1.23 to -0.66, fail-safe number = 825) and hip (SMD = -0.534, 95 % CI = -0.876 to -0.192, fail-safe number = 186). A higher proportion of hyperprolactinaemia (β = -0.0102, p < 0.0001) and smokers (β = -0.0099, p = 0.02) moderated a larger reduced BMD at the lumbar spine. Further research is required to investigate if low bone mass and fractures can be prevented in people with schizophrenia.

Keywords: Bone mineral density; Fracture; Osteoporosis; Psychosis; Schizophrenia.

Publication types

  • Meta-Analysis
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Antipsychotic Agents / therapeutic use
  • Bone Density*
  • Hip Joint / diagnostic imaging*
  • Humans
  • Hyperprolactinemia / epidemiology
  • Lumbar Vertebrae / diagnostic imaging*
  • Osteoporosis / diagnostic imaging
  • Osteoporosis / epidemiology*
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / epidemiology*
  • Schizophrenia / drug therapy
  • Schizophrenia / epidemiology*
  • Smoking / epidemiology

Substances

  • Antipsychotic Agents